Prothena Corp. (PRTA) Stock Price Up 6.1%
Shares of Prothena Corp. (NASDAQ:PRTA) rose 6.1% during mid-day trading on Monday . The stock traded as high as $62.46 and last traded at $62.00, with a volume of 329,246 shares trading hands. The stock had previously closed at $58.43.
PRTA has been the topic of several recent analyst reports. Credit Suisse Group AG reiterated a “buy” rating on shares of Prothena Corp. in a research note on Friday, June 10th. Royal Bank Of Canada reissued a “buy” rating on shares of Prothena Corp. in a report on Friday, June 10th. Wedbush reissued an “outperform” rating and issued a $77.00 price objective on shares of Prothena Corp. in a report on Tuesday, July 5th. Finally, Barclays PLC lifted their price objective on Prothena Corp. from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Thursday, August 4th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Prothena Corp. presently has an average rating of “Buy” and an average price target of $76.80.
The company’s market capitalization is $2.10 billion. The firm’s 50 day moving average is $54.45 and its 200 day moving average is $45.62.
Prothena Corp. (NASDAQ:PRTA) last released its quarterly earnings results on Tuesday, August 2nd. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($0.91) by $0.27. The firm had revenue of $0.33 million for the quarter, compared to analysts’ expectations of $0.39 million. Prothena Corp. had a negative net margin of 8,628.11% and a negative return on equity of 28.15%. The business’s revenue was up 22.2% on a year-over-year basis. Analysts forecast that Prothena Corp. will post ($4.25) EPS for the current fiscal year.
In related news, insider Arthur W. Homan sold 9,375 shares of the business’s stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $52.14, for a total transaction of $488,812.50. Following the transaction, the insider now directly owns 9,375 shares in the company, valued at approximately $488,812.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Arthur W. Homan sold 3,125 shares of the business’s stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $52.16, for a total value of $163,000.00. Following the transaction, the insider now owns 3,125 shares in the company, valued at $163,000. The disclosure for this sale can be found here. 3.70% of the stock is owned by insiders.
Hedge funds have recently bought and sold shares of the stock. Sabby Management LLC acquired a new position in Prothena Corp. during the first quarter worth $1,646,000. Wellington Management Group LLP boosted its position in Prothena Corp. by 29.0% in the first quarter. Wellington Management Group LLP now owns 3,216,685 shares of the company’s stock worth $132,398,000 after buying an additional 722,889 shares during the last quarter. UBS Group AG boosted its position in Prothena Corp. by 5.4% in the first quarter. UBS Group AG now owns 21,504 shares of the company’s stock worth $886,000 after buying an additional 1,101 shares during the last quarter. State Street Corp boosted its position in Prothena Corp. by 51.3% in the first quarter. State Street Corp now owns 1,224,523 shares of the company’s stock worth $50,406,000 after buying an additional 415,089 shares during the last quarter. Finally, Cupps Capital Management LLC acquired a new position in Prothena Corp. during the first quarter worth $1,792,000.
About Prothena Corp.
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).
Receive News & Ratings for Prothena Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.